Tenofovir Alafenamide

Routes
Oral (PO)
Half-Life (t½)
PO: 26m
Formula
C21H29N6O5P
Molecular Weight
476.47 g/mol
PubChem CID
9574768
Aliases
TAF

Pharmacological Mechanism

Newer prodrug of tenofovir — preferential cleavage by lymphocyte cathepsin A → higher intracellular tenofovir-DP with much lower plasma tenofovir vs TDF. Reduced renal + bone toxicity. Replaces TDF in modern combination ART regimens.

Half-Life & Elimination Curve (PO: 26m)

100%50%25%12.5%0%0h0×t½26m1×t½52m2×t½1.29h3×t½1.72h4×t½2.15h5×t½0×t½ (0h): 100% remaining (~42.3 µg/L)1×t½ (26m): 50% remaining (~21.2 µg/L)2×t½ (52m): 25% remaining (~10.6 µg/L)3×t½ (1.29h): 12.5% remaining (~5.29 µg/L)4×t½ (1.72h): 6.3% remaining (~2.64 µg/L)5×t½ (2.15h): 3.1% remaining (~1.32 µg/L)
Plasma (PO)t½ Decay (26m)
  • 0×t½0h100% (42.3 µg/L)
  • 1×t½26m50% (21.2 µg/L)
  • 2×t½52m25% (10.6 µg/L)
  • 3×t½1.29h12.5% (5.29 µg/L)
  • 4×t½1.72h6.3% (2.64 µg/L)
  • 5×t½2.15h3.1% (1.32 µg/L)
Elimination t½26m (PO)
Rate Constant (ke)1.61 h⁻¹
Time to Peak (Tmax)23m
Est. Peak (Cmax)42.3 µg/L
Clearance (CL)129 L/h
97% Washout (5×t½)2.15h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References